OBSV News and Press, ObsEva SA From 12/07/19

The following list reflects actual dividend paying stocks that I hold in my personal portfolio: Barings BDC, Inc. ( BBDC ), BlackRock Capital Investment ( BKCC ), Blueknight Energy Partners - PFD Units ( BKEPP ), BlackRock Income Trust ( BKT ), BlackRock Enhanced Equity Dividend Trust ( BDJ ),...

  Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phas...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was on the rise again last week, increasing from 3,602.55 points on Monday’s (November 25) open to 3,755.88 points as of 1:00 p.m. EST on Friday (November 29). On Wednesday (November 27), Verrica Pharmaceuticals (NASDAQ: VRCA ) revea...

Image source: The Motley Fool. ObsEva SA   (NASDAQ: OBSV) Q3 2019 Earnings Call Nov 11, 2019 , 2:00 p.m. ET Operator Continue reading

Gainers: DRTT  +7.9% . EGO   +3.2% . AU   +1.9% . OBSV   +1.7% . More news on: Eldorado Gold Corporation, AngloGold Ashanti Limited, ObsEva SA, Stocks on the move, Read more ...

Dermira (NASDAQ: DERM ) +29%  on apparent reaction to AnaptysBio's  etokimab flop  in a mid-stage atopic dermatitis study. More news on: Dermira, Inc., ObsEva SA, Sientra, Inc., Stocks on the move, Read more ...

CdbMD (NYSEMKT: YCBD ) initiated with Neutral rating and $3.40 (15% downside risk) price target at Cantor Fitzgerald. More news on: cbdMD, Inc., CV Sciences, Inc., Portola Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

ObsEva SA (NASDAQ: OBSV ) is down  24%  premarket on light volume in reaction to its announcement that lead drug nolasiban failed to achieve the primary endpoint in a Phase 3 clinical trial, IMPLANT4 , aimed at demonstrating that a single oral dose increased the pregnancy rate i...

ObsEva (NASDAQ: OBSV ): Q3 GAAP EPS of -$0.63 beats by $0.19 . Cash and cash equivalents of $91M Press Release More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news,

– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET – &#...